Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI ® (encorafenib) in combination with cetuximab ...
The biliary tract cancer epidemiology section provides insights into the historical and current biliary tract cancer patient pool and forecasted trends for the leading markets. In 2024, the majority ...
Pfizer (PFE) looks undervalued at 8–9x forward earnings with a ~7% yield; see how Seagen, cost cuts and the pipeline could drive $36–42 upside—read now.
The stock is down, but the good news is that it sports a fat dividend yield of 6.4%. Pfizer has been struggling lately, but it has a rich pipeline of drugs in development. The pharmaceutical giant ...
If you ask me for a reason I'd buy Pfizer (NYSE: PFE) stock and never sell it, I certainly have one -- because I've already bought into Pfizer, and I have no plans to sell it. Here's a look at why I ...
Rich Pelt, senior director of Global Regulatory Sciences at Pfizer gives tips for navigating the rapidly changing regulatory ...
White House war promo videos marry action movies, sports and video games to real-life combat footage
Peaceful and violent, in video game screenshots and movie clips and on professional playing fields, the icons come fast and ...
Three young women will take the stage to compete in the Miss La Paz County Scholarship Competition, alongside three young ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results